Ultrasonic Wound Debridement vs. Standard Sharp Debridement
Ultrasonic Surgical Wound Debridement vs. Standard Sharp Debridement In the Treatment of Chronic Wounds: A Single Center, Randomized, Parallel, Clinical Outcome Trial
1 other identifier
interventional
75
1 country
1
Brief Summary
A single center, randomized, parallel, clinical outcome trial to compare the rate of healing in chronic wounds debrided with either high energy ultrasonic debridement (with cavitation) or standard of care sharp debridement.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2008
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2008
CompletedFirst Submitted
Initial submission to the registry
November 8, 2010
CompletedFirst Posted
Study publicly available on registry
November 9, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2011
CompletedStudy Completion
Last participant's last visit for all outcomes
April 1, 2011
CompletedJuly 24, 2014
July 1, 2014
2.8 years
November 8, 2010
July 22, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Time to complete wound closure
12 and 24 weeks
Secondary Outcomes (1)
Relative rate of wound healing
8, 12 and 24 weeks
Study Arms (2)
Contact Ultrasonic Debridement Device
ACTIVE COMPARATORStandard Sharp Debridement
ACTIVE COMPARATORInterventions
Cavitational ultrasound wound debridement device
Eligibility Criteria
You may qualify if:
- Chronic wound needing debridement \>3 cm2
- Ulcer history \>4mo
- Adequate arterial blood flow (ABI\>0.7)
- Venous, Inflammatory, Pressure, Diabetic
You may not qualify if:
- Bleeding disorder
- ABI\<0.7
- Uncontrolled diabetes
- Taking systemic corticosteroids
- Chemotherapy
- Participating in another study
- Treatment with Apligraft, Dermagraft, or Regranex within 90 days
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Calvary Hospital Center for Curative and Palliative Wound Care
The Bronx, New York, 10461, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Oscar M Alvarez, PhD
Director, Wound care Center, Calvary Hospital
- STUDY DIRECTOR
Martin E Wendelken, DPM, RN
Physician, Wound Care Center, Calvary Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Center for Curative and Palliative Wound Care
Study Record Dates
First Submitted
November 8, 2010
First Posted
November 9, 2010
Study Start
June 1, 2008
Primary Completion
April 1, 2011
Study Completion
April 1, 2011
Last Updated
July 24, 2014
Record last verified: 2014-07